CRISPR Therapeutics AG (CRSP) vs Iovance Biotherapeutics, Inc. (IOVA)

CRISPR Therapeutics AG and Iovance Biotherapeutics, Inc. are both Biotechnology companies. CRISPR Therapeutics AG is the larger, with a market value of $5.4B against $4.9B — 1.1× the size. Iovance Biotherapeutics, Inc. grew revenue faster over the last twelve months: 34.6% against −64.8%. Iovance Biotherapeutics, Inc. has the higher net margin (−89.1% vs −3,368.7%) and the lower return on invested capital (−43.0% vs 0.00%). Across the 17 metrics below, Iovance Biotherapeutics, Inc. leads on 11 and CRISPR Therapeutics AG on 6.

Valuation

Metric CRSP IOVA Biotechnology median
P/E n/m n/m 7.88
P/S 390.83 15.24 11.47
P/B 3.00 6.73 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 258.05 14.33 10.73
Earnings yield (8.78%) (6.64%) (28.84%)
Free cash flow yield (7.09%) (5.99%) (23.03%)

Profitability

Metric CRSP IOVA Biotechnology median
Gross margin 100.00% 48.40% 65.16%
Operating margin (3,989.99%) (92.72%) 0.00%
Net margin (3,368.72%) (89.09%) 0.00%
Free cash flow margin (2,772.74%) (91.21%) 0.00%
Return on equity (26.09%) (40.36%) (57.72%)
Return on assets (19.28%) (31.76%) (49.22%)
Return on invested capital 0.00% (42.96%) 0.00%

Growth

Metric CRSP IOVA Biotechnology median
Revenue growth (TTM) (64.80%) 34.55% 5.64%
EPS growth (last fiscal year) (49.08%) 14.84% —
Revenue growth, 5-year CAGR 37.31% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRSP IOVA Biotechnology median
Debt to equity 0.34 0.00 0.00
Current ratio 17.85 4.35 4.73
Net debt to EBITDA 3.06 0.82 0.96

Dividend

Metric CRSP IOVA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CRSP IOVA Biotechnology median
Market cap 5.39b 4.90b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack